Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 3/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1673183 | 0.86 | SYK (0.32) | SYK | |
| SCHEMBL19045190 | 0.81 | PDE4A (0.33) | SYKTSHRGAAPDE4APDE4B | |
| SCHEMBL1672816 | 0.81 | SYK (0.33) | SYK | |
| SCHEMBL21550321 | 0.81 | SYK (0.33) | SYK | |
| SCHEMBL6950382 | 0.81 | SYK (0.33) | SYK | |
| SCHEMBL12069210 | 0.80 | IRAK4 (0.34) | SYK | |
| SCHEMBL23314230 | 0.79 | CRBN (0.33) | SYKCRBN | |
| SCHEMBL19465901 | 0.79 | OPRL1 (0.34) | — | |
| SCHEMBL12690045 | 0.78 | SYK (0.32) | SYK | |
| SCHEMBL2947840 | 0.78 | SYK (0.34) | SYKFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230276788-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20210100238-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | X-THERMA, INC. (US) | 2021-04-08 | — | — | US | disclosed |
| US-10694739-B2 | Compositions and methods for reducing ice crystal formation | X-THERMA, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190069537-A1 | Compositions and Methods for Reducing Ice Crystal Formation | X-THERMA, INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-9986733-B2 | Compositions and methods for reducing ice crystal formation | X-THERMA, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170295777-A1 | Compositions and Methods for Reducing Ice Crystal Formation | X-THERMA, INC. (US) | 2017-10-19 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | SYK 1943/4885TSHR 2377/4885GAA 233/4885 |
| US-20170295777-A1 | Compositions and Methods for Reducing Ice Crystal Formation | CUTA, IAPP, CRYAA | SYK 4315/4885TSHR 3966/4885GAA 2998/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | SYK 1943/4885TSHR 2377/4885GAA 233/4885 |
| US-20190069537-A1 | Compositions and Methods for Reducing Ice Crystal Formation | CUTA, IAPP, CRYAA | SYK 4315/4885TSHR 3966/4885GAA 2998/4885 |
| US-20210100238-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | CUTA, IAPP, CRYAA | SYK 4315/4885TSHR 3966/4885GAA 2998/4885 |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | KRAS, NRAS, HRAS | SYK 3573/4885TSHR 3893/4885GAA 1891/4885 |
| US-10694739-B2 | Compositions and methods for reducing ice crystal formation | CUTA, IAPP, CRYAA | SYK 4315/4885TSHR 3966/4885GAA 2998/4885 |
| US-20230276788-A1 | COMPOSITIONS AND METHODS FOR REDUCING ICE CRYSTAL FORMATION | CUTA, IAPP, CRYAA | SYK 4315/4885TSHR 3966/4885GAA 2998/4885 |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | SYK 1023/4885TSHR 3921/4885GAA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.